As of April 29, 2025, VYNE Therapeutics (VYNE) has a market cap of $21.446 million USD. According to our data, VYNE Therapeutics is ranked No.8539 in global market value.
Year | Market Cap | %Change |
---|---|---|
Apr 29, 2025 | $21.45 M |
-56.60%
|
Dec 31, 2024 | $49.42 M |
43.78%
|
Dec 29, 2023 | $34.37 M |
-13.70%
|
Dec 30, 2022 | $39.83 M |
-85.29%
|
Dec 31, 2021 | $0.27 B |
-83.86%
|
Dec 31, 2020 | $1.68 B |
-65.95%
|
Dec 31, 2019 | $4.93 B |
12.62%
|
Dec 31, 2018 | $4.38 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
![]() Eli Lilly
LLY
|
$794.90 B |
-0.026 M
|
![]() USA
|
![]() Johnson & Johnson
JNJ
|
$375.13 B |
0.006 M
|
![]() USA
|
![]() AbbVie
ABBV
|
$342.32 B |
-0.001 M
|
![]() USA
|
![]() Novo Nordisk
NVO
|
$290.79 B |
71.582 B
|
![]() Denmark
|
![]() Novo Nordisk A/S
NOVO-B.CO
|
$277.07 B |
63.951 B
|
![]() Denmark
|
![]() Roche
ROG.SW
|
$263.24 B |
40.907 B
|
![]() Switzerland
|
![]() Novartis
NVS
|
$224.23 B |
0.160 B
|
![]() Switzerland
|
![]() AstraZeneca
AZN
|
$222.30 B |
0.004 M
|
![]() UK
|
![]() Merck
MRK
|
$212.01 B |
-0.001 M
|
![]() USA
|
![]() Thermo Fisher Scientific
TMO
|
$159.05 B |
0.003 M
|
![]() USA
|
![]() Amgen
AMGN
|
$152.20 B |
0.126 B
|
![]() USA
|
![]() Gilead Sciences
GILD
|
$132.39 B |
-0.001 M
|
![]() USA
|
![]() Pfizer
PFE
|
$130.73 B |
-0.001 M
|
![]() USA
|
![]() Sanofi
SNY
|
$128.86 B |
0.003 M
|
![]() France
|
![]() Vertex Pharmaceuticals
VRTX
|
$127.64 B |
0.004 M
|
![]() USA
|
![]() Bristol-Myers Squibb
BMY
|
$98.62 B |
0.002 M
|
![]() USA
|
![]() Chugai Pharmaceutical
4519.T
|
$92.78 B |
0.001 M
|
![]() Japan
|
![]() CVS Health
CVS
|
$81.97 B |
-0.002 M
|
![]() USA
|
![]() GlaxoSmithKline
GSK
|
$77.05 B |
0.003 M
|
![]() UK
|
![]() CSL
CSL.AX
|
$76.39 B |
0.355 B
|
![]() Australia
|
Market Cap | = | VYNE Stock Price | * | VYNE Shares Outstanding |
= | $1.41 | * | 15.21 M | |
= | $21.45 M |